Cardiac amyloidosis is a serious and progressive infiltrative disease caused by the deposition of amyloid fibrils in the heart. In the last years, a significant increase in the diagnosis rate has been observed owing to a greater awareness of its broad clinical presentation. Cardiac amyloidosis is frequently associated to specific clinical and instrumental features, so called “red flags”, and it appears to occur more commonly in particular clinical settings such as multidistrict orthopedic conditions, aortic valve stenosis, heart failure with preserved or mildly reduced ejection fraction, arrhythmias, plasma cell disorders. Multimodality approach and new developed techniques such PET fluorine tracers or artificial intelligence may contribute to strike up extensive screening programs for an early recognition of the disease.

Caponetti A.G., Accietto A., Saturi G., Ponziani A., Sguazzotti M., Massa P., et al. (2023). Screening approaches to cardiac amyloidosis in different clinical settings: Current practice and future perspectives. FRONTIERS IN CARDIOVASCULAR MEDICINE, 10, 1-10 [10.3389/fcvm.2023.1146725].

Screening approaches to cardiac amyloidosis in different clinical settings: Current practice and future perspectives

Caponetti A. G.;Accietto A.;Saturi G.;Ponziani A.;Sguazzotti M.;Giovannetti A.;Ditaranto R.;Parisi V.;Guaraldi P.;Cortelli P.;Gagliardi C.;Longhi S.;Galie N.;Biagini E.
2023

Abstract

Cardiac amyloidosis is a serious and progressive infiltrative disease caused by the deposition of amyloid fibrils in the heart. In the last years, a significant increase in the diagnosis rate has been observed owing to a greater awareness of its broad clinical presentation. Cardiac amyloidosis is frequently associated to specific clinical and instrumental features, so called “red flags”, and it appears to occur more commonly in particular clinical settings such as multidistrict orthopedic conditions, aortic valve stenosis, heart failure with preserved or mildly reduced ejection fraction, arrhythmias, plasma cell disorders. Multimodality approach and new developed techniques such PET fluorine tracers or artificial intelligence may contribute to strike up extensive screening programs for an early recognition of the disease.
2023
Caponetti A.G., Accietto A., Saturi G., Ponziani A., Sguazzotti M., Massa P., et al. (2023). Screening approaches to cardiac amyloidosis in different clinical settings: Current practice and future perspectives. FRONTIERS IN CARDIOVASCULAR MEDICINE, 10, 1-10 [10.3389/fcvm.2023.1146725].
Caponetti A.G.; Accietto A.; Saturi G.; Ponziani A.; Sguazzotti M.; Massa P.; Giovannetti A.; Ditaranto R.; Parisi V.; Leone O.; Guaraldi P.; Cortelli...espandi
File in questo prodotto:
File Dimensione Formato  
fcvm-10-1146725.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 89.31 MB
Formato Adobe PDF
89.31 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/955768
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact